• T+44 (0)20 3116 3640
    F+44 (0)20 3116 3999

John Wilkinson

Advised Addex Pharmaceuticals on two significant licences with Merck & Co Inc
Advised ALK-Abelló A/S on its co-promotion and licence agreements with Menarini
Advised ALK-Abelló A/S on its licence and development agreement with Schering Plough
Advised ALK-Abelló A/S on its recombinant allergen development agreement with Novozymes
Advised AstraZeneca on its strategic alliance with Cambridge Antibody Technology and the commercial and IP due diligence on the subsequent acquisition of a Cambridge Antibody Technology
Advised Cambridge Consultants on the licensing of inhaler technology to 3M
Advised Cellzome on a major strategic alliance with GSK
Advised Cowen Healthcare Royalty Partners on the IP aspects of their acquisition of AeternaZentaris royalty interest in Cetrotide
Advising EUSA Pharma on its acquisition of Taliska and French company, OPi
Advised Meda AB on its $392m acquisition of Valeant Pharmaceutical Inc.s Western and Eastern European and Middle Eastern businesses
Results: 1 - 10 of 13